Phentermine/topiramate - VIVUS
Alternative Names: Phentermine and topiramate extended-release capsules - VIVUS; Phentermine/CR topiramate - VIVUS; Qnexa; Qsiva; Qsymia; Topiramate/phentermine; VI-0521Latest Information Update: 28 Jul 2024
At a glance
- Originator VIVUS
- Developer Alvogen; VIVUS
- Class Amphetamines; Anorectics; Antihyperglycaemics; Dioxolanes; Hepatoprotectants; Hexoses; Ketoses; Sleep disorder therapies; Small molecules; Sulfonic acids
- Mechanism of Action Adrenergic receptor agonists; AMPA receptor antagonists; Carbonic anhydrase inhibitors; Central nervous system stimulants; GABA A receptor agonists; Glutamate agonists; Kainic acid receptor antagonists; Neurotransmitter stimulants; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Obesity
- Phase II Sleep apnoea syndrome; Type 2 diabetes mellitus
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 05 Jul 2022 Phentermine/topiramate is still in clinical-Phase-Unknown development in Obesity (In adolescents, In children) in USA (PO, Controlled release)
- 05 Jul 2022 VIVUS completes the phase III EQUIP (OB-302) trial for Obesity in the US (PO) (NCT00554216)